Skip to main content

Media Center

Latest News

This filter choice is only applicable to the "Article" news type.
May 18, 2021

Washington, D.C. - Today, Rep. Jerrold Nadler, Chairman of the Committee on the Judiciary, Rep. Carolyn B. Maloney, Chairwoman of the Committee on Oversight and Reform, and Rep. David N.


May 18, 2021

Washington, D.C. - Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening remarks, as prepared, during the markup of H.R. 2922, the Elder Abuse Protection Act of 2021:


May 18, 2021

Washington, D.C. - Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening remarks during the markup of H.R. 2746, To amend title 28, United States Code, to redefine the eastern and middle judicial districts of North Carolina:


May 13, 2021

Washington, D.C. - Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening remarks, as prepared, during a Subcommittee on Crime, Terrorism, and Homeland Security hearing on "Juvenile Justice Pipeline and the Road Back to Integration:"


May 12, 2021

Washington, D.C. - Today, the House Judiciary Committee and the Department of Justice filed a joint motion to postpone oral argument in Judiciary v. McGahn after reaching agreement on a settlement for the testimony of former White House Counsel Don McGahn. Under the terms of the settlement, the Committee expects Mr. McGahn to appear for a transcribed interview. In that session, Mr. McGahn will respond to questions about Special Counsel Robert Mueller's investigation, allegations of obstruction of justice, and former President Trump's attack on Mr. McGahn's credibility.


May 5, 2021

Washington, D.C. - Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening remarks during a hearing on "Oversight of the U.S. Copyright Office:"


April 29, 2021

Washington, D.C. - During a hearing of the House Judiciary Antitrust Subcommittee today, lawmakers announced the introduction of a new bipartisan legislative package that will enhance efforts to lower prescription drug costs by taking on anticompetitive practices employed by large pharmaceutical companies.

Issues: Antitrust